INFLUENCE OF AMPICILLIN/CLOXACILLIN ON THE PHARMACOKINETICS OF CHLORPROPAMIDE IN TYPE II DIABETES MELLITUS PATIENTS
INFLUENCE OF AMPICILLIN/CLOXACILLIN ON THE PHARMACOKINETICS OF CHLORPROPAMIDE IN TYPE II DIABETES MELLITUS PATIENTS
No Thumbnail Available
Date
1999
Authors
ISAAC, ENEMALI SHAIBU
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Infection is very common in diabetics and its treatment should be prompt. This study
is to examine the influence of ampiclox (Ampicillin/Cloxacillin) Capsules on the
pharmacokinetics of chlorpropamide tablets in Type II diabetic patients. Seven type
II diabetic patients with age ranging from 35-70 yrs, weight ranging from 55-70 kg
and height from 1.65 - 1.78m participated in the study. Each patient received the
following treatments at two weeks interval:
250mg Chlorpropamide tablet alone and one 250mg Chloropromede table with one
500mg Ampiclox capsule.
Blood samples were taken at intervals for 168hours. Plasma Samples were
analysed by sp8 - 100 spectrophotometer. The plasma peak concentration (Cmax),
the amount of drug absorbed (AUC) and the elimination half - life (t½e[) were all
significantly (P<0.05) increased following the second treatment with the lag-time.
The statistical analysis was carried out using student t- test for paired data.
The elimination rate constant (Ket), the clearance time CI and the apparent volume
of distribution (Vd) were significantly (P<0.05) reduced following the second
treatment.
Ampiclox might have competitively displaced chlorpropamide from the biding site
thus giving rise to higher bioavailability and Cmax in the second treatment compared
with treatment. The effect of higher bioavaibility and Cmax followinj-the second
treatment can be observed by the significant (P<0.05) reduction in the plasma
glucose level following the second treatment compared with the first. Co administration
of ampiclox with, the long acting chlorpropamide may also affect the
renal tubular secretion of the later drug thus slowing down its tubular secretion
which can lead to reduced Clearance rate. Thus, the second treatment resulted in
increased bioavailability of chlorpropamide with longer half - life of elimination.
Description
A THESIS SUBMITTED TO THE POSTGRADUATE SCHOOL,
AHMADU BELLO UNIVERSITY, ZARIA IN PARTIAL
FULFILLMENT OF THE REQUIREMENTS FOR THE AWARD OF
THE DEGREE OF MASTER OF SCIENCE IN
PHARMACEUTICAL CHEMISTRY
DEPARTMENT OF PHARMACEUTICAL AND MEDICINAL
CHEMISTRY , FACULTY OF PHARMACEUTICAL SCIENCES,
AHMADU BELLO UNIVERSITY
ZARIA, NIGERIA
1999
Keywords
INFLUENCE,, AMPICILLIN/CLOXACILLIN,, PHARMACOKINETICS,, CHLORPROPAMIDE,, DIABETES,, MELLITUS PATIENTS